Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	273M 238M 224M 204M 382M 26.18B 384M 2.68B 1.04B 13.32B 1.03B 1B 42.83B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	369M 321M 303M 276M 516M 35.39B 519M 3.63B 1.4B 18B 1.39B 1.36B 57.9B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.2x
Free-Float	95.22%	Yield 2026 *	-	Yield 2027 *	-

08-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-14	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/10/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI

08-15	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
08-06	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-16	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

Northwest Biotherapeutics, Inc. Stock Other OTC

Stocks

NWBO

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc.

Latest news: Northwest Biotherapeutics, Inc.

Press Releases: Northwest Biotherapeutics, Inc.

Quotes and Performance

Managers and Directors: Northwest Biotherapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	-6.38%	-8.82%	-	-	282M
WUXI APPTEC CO., LTD.	-0.31%	+3.56%	+46.40%	+100.50%	70.89B
ARGENX SE	+0.39%	+1.82%	+38.93%	+77.73%	62.32B
INSMED INCORPORATED	-3.21%	-5.72%	-17.12%	+350.96%	27.07B
BIONTECH SE	-2.64%	-0.35%	-2.13%	-15.04%	24.78B
GENMAB A/S	+0.71%	+8.50%	+27.76%	-15.29%	20.59B
PHARMAESSENTIA CORPORATION	-1.26%	-10.61%	+170.72%	+290.48%	15.52B
EXELIXIS, INC.	-0.22%	+1.62%	+44.31%	+167.58%	14.49B
SUMMIT THERAPEUTICS INC.	+0.73%	+5.00%	-1.33%	+854.55%	14.14B
MADRIGAL PHARMACEUTICALS, INC.	-0.54%	-0.30%	+27.33%	+202.19%	12.35B
Average	-1.27%	+1.68%	+37.21%	+223.74%	29.13B
Weighted average by Cap.	-0.60%	+1.39%	+35.79%	+161.34%

	2026 *	2027 *
Net sales	-	38.93M 33.9M 32M 29.07M 54.44M 3.73B 54.71M 383M 148M 1.9B 146M 143M 6.11B
Net income	-	-
Net Debt	96.08M 83.65M 78.96M 71.74M 134M 9.21B 135M 944M 365M 4.68B 361M 353M 15.07B	125M 109M 103M 93.29M 175M 11.98B 176M 1.23B 474M 6.09B 469M 459M 19.6B